If GNG7 indeed facilitates tumor-specific immune responses, its expression could serve not only as a predictive biomarker for the efficacy of immunotherapy, but also as a potential therapeutic target to reverse resistance to immune checkpoint inhibitors (ICIs). The gene discussed is GNG7; the disease is neoplasm.